Adding Silo Pharma (SILO) $3.50 to Watch List.

Look What We Found! We launched the Psychedelic Stock Review a little more than a year ago and decided...

Revive Therapeutics (RVVTF) Enters the Danger Zone.

What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.
ehave

Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.

MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...

Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?

Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Revive Therapeutics

Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...

Two Binary Events Directly Ahead. As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics

Revive Therapeutics (RVVTF, RVV): Updates and News Archive.

Recent Headlines (See FDA Filing Submission at Bottom) LIVE QUOTE

Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs

IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs

Ehave’s Mobile Ketamine Clinic, Rolling into Town.

Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
Psychedelic Stock Review

Coming This Monday..

Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...

Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught...

Latest article

Society Pass (SOPA) $1.15 Breaks Above First Line of Resistance.

Just a Quick Heads Up. Price and Volume Gradually Picking up From Where we Added to Watch List on the 12th.

Silo Pharma (SILO) $2.67 Announces $1 Million Stock Buyback.

Yes it doesn't sound like a lot of money on the surface. But the stock is so grossly undervalued (in our opinion)...

Three That Doubled, Three More That May Double.

Ardelyx $3.00 (ARDX) Gains 117%, Provention Bio $8.75 (PRVB) Gains 134%, and PharmaTher (PHRRF) up 154%. Blue Skies Ahead - For All...